cfdna methylation markers Search Results


cfdna methylation markers  (Stackpole Electronics)
90
Stackpole Electronics cfdna methylation markers
Studies on the use of ctDNA analysis for early detection of lung cancer
Cfdna Methylation Markers, supplied by Stackpole Electronics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cfdna methylation markers/product/Stackpole Electronics
Average 90 stars, based on 1 article reviews
cfdna methylation markers - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
hepatocyte-specific cfdna methylation markers  (Wolters Kluwer Health)
90
Wolters Kluwer Health hepatocyte-specific cfdna methylation markers
Studies on the use of ctDNA analysis for early detection of lung cancer
Hepatocyte Specific Cfdna Methylation Markers, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hepatocyte-specific cfdna methylation markers/product/Wolters Kluwer Health
Average 90 stars, based on 1 article reviews
hepatocyte-specific cfdna methylation markers - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Studies on the use of ctDNA analysis for early detection of lung cancer

Journal: Annals of Translational Medicine

Article Title: Circulating tumour DNA analysis for early detection of lung cancer: a systematic review

doi: 10.21037/atm-23-1572

Figure Lengend Snippet: Studies on the use of ctDNA analysis for early detection of lung cancer

Article Snippet: 36175411 , Stackpole et al. , 2022 ( ) , Pan-cancer , cfDNA methylation markers , 23,748 cancer-specific hypermethylation markers, 28,197 cancer-specific hypomethylation markers, 7,547 tissue-specific hypermethylation markers, 7,212 tissue-specific hypomethylation markers , Lung cancer (N=126), other cancers (N=150); stage I/II/III/IV =33/23/30/40, histological subtype (LUAD/LUSC) =77/49 , Non-cancer (healthy individuals and patients of various noncancer diseases (e.g., cirrhosis, pancreatitis, hepatitis, diabetes, etc.), N=203) , Integrating four marker types (all cancer types (n=217) vs. noncancer (n=191): sen./spec.=80.7%/97.9%, AUC =0.974.

Techniques: Biomarker Discovery, Concentration Assay, Amplification, Mutagenesis, Control, Clinical Proteomics, Methylation, DNA Methylation Assay, Computed Tomography, In Situ, Marker, Comparison, Diagnostic Assay, Genome Wide, RNA Expression